Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 454

1.

Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.

Hozumi K, Fukuoka H, Odake Y, Takeuchi T, Uehara T, Sato T, Inoshita N, Yoshida K, Matsumoto R, Bando H, Hirota Y, Iguchi G, Taniguchi M, Otsuki N, Nishigori C, Kosaki K, Hasegawa T, Ogawa W, Takahashi Y.

Endocr J. 2019 Jun 12. doi: 10.1507/endocrj.EJ19-0035. [Epub ahead of print]

2.

CXCR4 regulates Plasmodium development in mouse and human hepatocytes.

Bando H, Pradipta A, Iwanaga S, Okamoto T, Okuzaki D, Tanaka S, Vega-Rodríguez J, Lee Y, Ma JS, Sakaguchi N, Soga A, Fukumoto S, Sasai M, Matsuura Y, Yuda M, Jacobs-Lorena M, Yamamoto M.

J Exp Med. 2019 Jun 12. pii: jem.20182227. doi: 10.1084/jem.20182227. [Epub ahead of print]

PMID:
31189656
3.

Human GBP1 is a microbe-specific gatekeeper of macrophage apoptosis and pyroptosis.

Fisch D, Bando H, Clough B, Hornung V, Yamamoto M, Shenoy AR, Frickel EM.

EMBO J. 2019 May 31. pii: e100926. doi: 10.15252/embj.2018100926. [Epub ahead of print]

4.

Toxoplasma Effector GRA15-Dependent Suppression of IFN-γ-Induced Antiparasitic Response in Human Neurons.

Bando H, Lee Y, Sakaguchi N, Pradipta A, Sakamoto R, Tanaka S, Ma JS, Sasai M, Yamamoto M.

Front Cell Infect Microbiol. 2019 May 1;9:140. doi: 10.3389/fcimb.2019.00140. eCollection 2019.

5.

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, Muro K.

J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.19.00003.

6.

Influence of Surgical Procedures and Instruments on the Incidence of Suprachoroidal Hemorrhage during 25-gauge Pars Plana Vitrectomy.

Iwama Y, Nakashima H, Emi K, Bando H, Ikeda T.

Ophthalmol Retina. 2018 Sep;2(9):888-894. doi: 10.1016/j.oret.2018.01.009. Epub 2018 Mar 3.

PMID:
31047220
7.

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.

Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, Yamanaka T, Yoshino T.

Br J Cancer. 2019 May;120(10):982-986. doi: 10.1038/s41416-019-0457-y. Epub 2019 Apr 24.

PMID:
31015557
8.

Efficiency of fluorescent cholangiography during laparoscopic cholecystectomy for subvesical bile ducts: A case report.

Kitamura H, Tsuji T, Yamamoto D, Takahashi T, Kadoya S, Kurokawa M, Bando H.

Int J Surg Case Rep. 2019;57:194-196. doi: 10.1016/j.ijscr.2019.03.042. Epub 2019 Mar 30.

9.

Differential isoform expression of SERCA and myosin heavy chain in hypopharyngeal muscles.

Ahmed ME, Bando H, Fuse S, Abdelfattah HM, Ahmed ME, Ahmed MA, Tsujikawa T, Hisa Y.

Acta Otorhinolaryngol Ital. 2019 Mar 25. doi: 10.14639/0392-100X-2185. [Epub ahead of print]

PMID:
30933182
10.

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.

Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.

BMC Cancer. 2019 Mar 21;19(1):255. doi: 10.1186/s12885-019-5479-6.

11.

The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.

Sagawa N, Ohno S, Hiratsuka T, Kondo N, Iwata H, Bando H, Ohyama T, Ishida M, Kono Y, Nakajima K, Empuku S, Nishikawa S, Irie Y, Inomata M, Kitano S.

Breast Cancer Res Treat. 2019 Aug;176(3):625-630. doi: 10.1007/s10549-019-05164-5. Epub 2019 Feb 26.

PMID:
30806921
12.

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.

Muro K, Itabashi M, Hashida H, Masuishi T, Bando H, Denda T, Yamanaka T, Ohashi Y, Sugihara K.

Jpn J Clin Oncol. 2019 Apr 1;49(4):339-346. doi: 10.1093/jjco/hyy189.

13.

Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M.

Breast Cancer. 2019 Feb 7. doi: 10.1007/s12282-019-00952-9. [Epub ahead of print]

PMID:
30734152
14.

Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.

Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K, Ishihara K, Kakizume T, Natsume K, Myers A, Doi T.

Cancer Sci. 2019 Apr;110(4):1340-1351. doi: 10.1111/cas.13956. Epub 2019 Feb 20.

15.

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K.

J Immunother Cancer. 2019 Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.

16.

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.

Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K.

Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.

PMID:
30627987
17.

IgG4-related hypophysitis in patients with autoimmune pancreatitis.

Kanie K, Bando H, Iguchi G, Shiomi H, Masuda A, Fukuoka H, Nishizawa H, Fujita Y, Sakai A, Kobayashi T, Shiomi Y, Yoshida K, Matsumoto R, Suda K, Kodama Y, Ogawa W, Takahashi Y.

Pituitary. 2019 Feb;22(1):54-61. doi: 10.1007/s11102-018-00930-y.

PMID:
30607745
18.

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.

Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K.

Ann Surg Oncol. 2019 Feb;26(2):465-472. doi: 10.1245/s10434-018-7063-8. Epub 2018 Nov 19.

PMID:
30456678
19.

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma.

Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K.

ESMO Open. 2018 Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018.

20.

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab.

Watanabe R, Nakano E, Kawazoe A, Kuboki Y, Bando H, Shitara K, Takahashi A, Tsutsumida A, Nishizawa A, Yamazaki N.

J Dermatol. 2019 May;46(5):e178-e180. doi: 10.1111/1346-8138.14693. Epub 2018 Oct 31. No abstract available.

PMID:
30379358
21.

Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response.

Bando H, Lee Y, Sakaguchi N, Pradipta A, Ma JS, Tanaka S, Cai Y, Liu J, Shen J, Nishikawa Y, Sasai M, Yamamoto M.

MBio. 2018 Oct 9;9(5). pii: e01738-18. doi: 10.1128/mBio.01738-18.

22.

Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-γ-Induced Anti-parasitic Response in Human Cells.

Bando H, Sakaguchi N, Lee Y, Pradipta A, Ma JS, Tanaka S, Lai DH, Liu J, Lun ZR, Nishikawa Y, Sasai M, Yamamoto M.

Front Immunol. 2018 Sep 19;9:2073. doi: 10.3389/fimmu.2018.02073. eCollection 2018.

23.

Insulin secretion of mixed insulinoma aggregates-gelatin hydrogel microspheres after subcutaneous transplantation.

Inoo K, Bando H, Tabata Y.

Regen Ther. 2018 Feb 2;8:38-45. doi: 10.1016/j.reth.2018.01.003. eCollection 2018 Jun.

24.

Enhanced survival and insulin secretion of insulinoma cell aggregates by incorporating gelatin hydrogel microspheres.

Inoo K, Bando H, Tabata Y.

Regen Ther. 2018 Feb 4;8:29-37. doi: 10.1016/j.reth.2017.12.002. eCollection 2018 Jun.

25.

Development and pharmacist-mediated use of tools for monitoring atypical antipsychotic-induced side effects related to blood glucose levels.

Ishida S, Takechi K, Bando H, Imanishi M, Zamami Y, Chuma M, Yanagawa H, Kirino Y, Nakamura T, Teraoka K, Ishizawa K.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1379-1384. doi: 10.1002/pds.4656. Epub 2018 Sep 17.

PMID:
30221424
26.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

27.

Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients.

Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino T.

Cancer Sci. 2018 Nov;109(11):3411-3415. doi: 10.1111/cas.13774. Epub 2018 Oct 2.

28.

Preoperative diagnosis of a giant cell tumor of soft tissue arising from the breast by ultrasound-guided core needle biopsy.

Sawa A, Ikeda T, Ichioka E, Tsushima Y, Iguchi-Manaka A, Bando H, Kondo Y, Hara H.

J Med Ultrason (2001). 2019 Apr;46(2):257-261. doi: 10.1007/s10396-018-0891-0. Epub 2018 Jul 30.

PMID:
30062496
29.

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies.

Sawada K, Kotani D, Bando H.

Front Oncol. 2018 Jul 16;8:263. doi: 10.3389/fonc.2018.00263. eCollection 2018. Review.

30.

Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome.

Bando H, Iguchi G, Kanie K, Nishizawa H, Matsumoto R, Fujita Y, Odake Y, Yoshida K, Suda K, Fukuoka H, Tanaka K, Ogawa W, Takahashi Y.

Pituitary. 2018 Oct;21(5):480-489. doi: 10.1007/s11102-018-0901-7.

PMID:
30008158
31.

Gallbladder Metastasis from Renal Cell Carcinoma.

Kitamura H, Kurokawa M, Inaki N, Bando H.

Indian J Surg. 2018 Jun;80(3):278-280. doi: 10.1007/s12262-017-1705-0. Epub 2017 Nov 27.

32.

Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.

Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I.

Gastric Cancer. 2019 Jan;22(1):138-146. doi: 10.1007/s10120-018-0845-7. Epub 2018 Jun 9.

PMID:
29948386
33.

Local control of sphincter-preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis.

Okamura R, Hida K, Yamaguchi T, Akagi T, Konishi T, Yamamoto M, Ota M, Matoba S, Bando H, Goto S, Sakai Y, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery, Watanabe K, Otsuka K, Takemasa I, Tanaka K, Ikeda M, Matsuda C, Fukuda M, Hasegawa J, Akamoto S, Shiozawa M, Tsuruta A, Akiyoshi T, Kato T, Tsukamoto S, Ito M, Naito M, Kanazawa A, Takahashi T, Ueki T, Hayashi Y, Morita S, Yamaguchi T, Nakanishi M, Hasegawa H, Okamoto K, Teraishi F, Sumi Y, Tashiro J, Yatsuoka T, Nishimura Y, Okita K, Kobatake T, Horie H, Miyakura Y, Ro H, Nagakari K, Hidaka E, Umemoto T, Nishigori H, Murata K, Wakayama F, Makizumi R, Fujii S, Sunami E, Kobayashi H, Nakagawa R, Enomoto T, Ohnuma S, Higashijima J, Ozawa H, Ashida K, Fujita F, Uehara K, Maruyama S, Ohyama M, Yamamoto S, Hinoi T, Yoshimitsu M, Okajima M, Tanimura S, Kawasaki M, Ide Y, Hazama S, Watanabe J, Inagaki D, Toyokawa A.

Ann Gastroenterol Surg. 2017 Aug 14;1(3):199-207. doi: 10.1002/ags3.12032. eCollection 2017 Sep.

34.

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T.

Gastric Cancer. 2019 Jan;22(1):69-76. doi: 10.1007/s10120-018-0843-9. Epub 2018 Jun 1.

PMID:
29859006
35.

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.

ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018.

36.

Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study.

Naito Y, Takahashi H, Shitara K, Okamoto W, Bando H, Kuwata T, Kuboki Y, Matsumoto S, Miki I, Yamanaka T, Watanabe A, Kojima M.

Jpn J Clin Oncol. 2018 Jun 1;48(6):559-564. doi: 10.1093/jjco/hyy052.

37.

Survival benefit of lymph node dissection in surgery for colon cancer in elderly patients: A multicenter propensity score-matched study in Japan.

Takahashi M, Niitsu H, Sakamoto K, Hinoi T, Hattori M, Goto M, Bando H, Hazama S, Maeda K, Okita K, Horie H, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery.

Asian J Endosc Surg. 2018 Nov;11(4):346-354. doi: 10.1111/ases.12474. Epub 2018 Mar 30.

PMID:
29601663
38.

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A.

Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9.

39.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.

Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S.

Breast Cancer. 2018 Jul;25(4):407-415. doi: 10.1007/s12282-018-0839-7. Epub 2018 Feb 14.

40.

Nomogram for predicting anastomotic leakage after low anterior resection for rectal cancer.

Hoshino N, Hida K, Sakai Y, Osada S, Idani H, Sato T, Takii Y, Bando H, Shiomi A, Saito N.

Int J Colorectal Dis. 2018 Apr;33(4):411-418. doi: 10.1007/s00384-018-2970-5. Epub 2018 Feb 6.

PMID:
29411120
41.

Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects.

Matsumoto R, Koga M, Kasayama S, Fukuoka H, Iguchi G, Odake Y, Yoshida K, Bando H, Suda K, Nishizawa H, Takahashi M, Ogawa W, Takahashi Y.

Growth Horm IGF Res. 2018 Jun;40:55-60. doi: 10.1016/j.ghir.2018.01.003. Epub 2018 Jan 31.

PMID:
29395967
42.

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.

Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, Shitara K.

BMC Cancer. 2018 Jan 31;18(1):120. doi: 10.1186/s12885-018-4057-7.

43.

Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing's Syndromes Treatment: Case Presentations.

Yoshida K, Fukuoka H, Odake Y, Nakajima S, Tachibana M, Ito J, Hosokawa Y, Yamada T, Miura H, Suematsu N, Matsumoto R, Bando H, Suda K, Nishizawa H, Iguchi G, Ogawa W, Takahashi Y.

Front Endocrinol (Lausanne). 2018 Jan 11;8:375. doi: 10.3389/fendo.2017.00375. eCollection 2017.

44.

Two Cases of Atezolizumab-Induced Hypophysitis.

Kanie K, Iguchi G, Bando H, Fujita Y, Odake Y, Yoshida K, Matsumoto R, Fukuoka H, Ogawa W, Takahashi Y.

J Endocr Soc. 2017 Dec 13;2(1):91-95. doi: 10.1210/js.2017-00414. eCollection 2018 Jan 1.

45.

A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.

Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T, Hironaka S, Komatsu Y, Shitara K.

Eur J Cancer. 2018 Mar;91:86-91. doi: 10.1016/j.ejca.2017.11.032. Epub 2018 Jan 30.

46.

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.

Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H.

Oncogene. 2018 Mar;37(13):1775-1787. doi: 10.1038/s41388-017-0035-9. Epub 2018 Jan 19.

PMID:
29348459
47.

Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.

Hamaguchi T, Shimada Y, Mizusawa J, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Takiguchi N, Yatsuoka T, Takii Y, Ojima H, Masuko H, Kubo Y, Mishima H, Yamaguchi T, Bando H, Sato T, Kato T, Nakamura K, Fukuda H, Moriya Y.

Lancet Gastroenterol Hepatol. 2018 Jan;3(1):47-56. doi: 10.1016/S2468-1253(17)30297-2. Epub 2017 Oct 24.

PMID:
29079411
48.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

49.

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.

Ohgami M, Bando H, Ishiguro H, Tsuda M, Toriguchi N, Aogi K, Toi M, Masuda N, Mitsuhashi S, Kurosawa A, Homma M.

Ann Oncol. 2017 Nov 1;28(11):2888-2889. doi: 10.1093/annonc/mdx328. No abstract available.

PMID:
28655197
50.

High efficacy in vitro selection procedure for generating transgenic parasites of Plasmodium berghei using an antibiotic toxic to rodent hosts.

Soga A, Bando H, Ko-Ketsu M, Masuda-Suganuma H, Kawazu SI, Fukumoto S.

Sci Rep. 2017 Jun 21;7(1):4001. doi: 10.1038/s41598-017-04244-0.

Supplemental Content

Support Center